GSK announces core EPS of 112.2p and dividend of 78p

• Core EPS of 112.2p (+4% CER) and dividend of 78p (+5%)
• £5.2 billion of cash returned to shareholders through 5% increase in 2013 dividend to 78p, (Q4 23p) and repurchase of £1.5 billion of shares
• Exceptional year for RD delivery with approvals forsix major products andfive additional regulatory filings completed
• New product launches strengthen businesses in Respiratory, Vaccines, HIV and Oncology

Pipeline opportunity remains substantial with Phase III data forsix potential new drugs and vaccines and aroundten NME Phase III starts across 2014 and 2015.

View full Q4 2013 results (PDF)

More details with CEO and CFO interview available in the quarterly results section of this website.